Replies to post #208060 on Biotech Values

[mcbio]

RARX/OMER -

They may be wasting a good deal of time and money. OMS-721 will also be available via sub Q administration.

I think OMER's OMS-721 has a bit further to go in the clinic before you can count on it being a success. Also, they are pursuing a completely different target so remains to be see if any advantages or disadvantages on safety/efficacy front vs. targeting C5. I'd like to look in to OMER again as they are pursuing new and novel targets for these indications (MASP-2 and MASP-3) but I don't really like the debt deals they do.